A randomized, double-blind, placebo-controlled, 4-period 4-treatment crossover, multi-center, dose ranging study, to assess the efficacy and safety of 3 single doses of indacaterol (150, 300 and 600 microg) delivered via a single dose dry powder inhaler in Japanese patients with chronic obstructive pulmonary disease (COPD).

Trial Profile

A randomized, double-blind, placebo-controlled, 4-period 4-treatment crossover, multi-center, dose ranging study, to assess the efficacy and safety of 3 single doses of indacaterol (150, 300 and 600 microg) delivered via a single dose dry powder inhaler in Japanese patients with chronic obstructive pulmonary disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 16 Sep 2008 Actual patient number changed from 48 to 50 as reported by Clinicaltrials.gov.
    • 08 Aug 2008 Actual patient number (48) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top